The chronic autoimmune thyroiditis quality of life selenium trial (CATALYST): study protocol for a randomized controlled trial
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with chronic autoimmune thyroiditis have impaired health-related quality of life. The thyroid gland has a high selenium concentration, and specific selenoprotein enzyme families are crucial to immune function, and catalyze thyroid hormone metabolism and redox processes in thyroid cells. Previous randomized controlled trials have found that selenium supplementation decreases thyroid-disease-specific antibody levels. We hypothesize that selenium might be beneficial in the treatment of chronic autoimmune thyroiditis. METHODS/DESIGN: The CATALYST trial is an investigator-initiated randomized, blinded, multicentre clinical trial of selenium supplementation versus placebo in patients with chronic autoimmune thyroiditis. INCLUSION CRITERIA: age ≥18 years; serum thyroid peroxidase antibody level ≥100 IU/ml within the previous 12 months; treatment with levothyroxine and written informed consent. EXCLUSION CRITERIA: previous diagnosis of toxic nodular goitre, Graves' hyperthyroidism, postpartum thyroiditis, Graves' orbitopathy; previous antithyroid drug treatment, radioiodine therapy or thyroid surgery; immune-modulatory or other medication affecting thyroid function; pregnancy, planned pregnancy or breastfeeding; allergy towards any intervention or placebo component; intake of selenium supplementation >55 μg/day; inability to read or understand Danish or lack of informed consent. The trial will include 2 × 236 participants. The experimental intervention and control groups will receive 200 μg selenium-enriched yeast or matching placebo tablets daily for 12 months. The experimental supplement will be SelenoPrecise®. The primary outcome is thyroid-related quality of life assessed by the Thyroid Patient-Reported Outcome (ThyPRO) questionnaire. Secondary outcomes include serum thyroid peroxidase antibody concentration; serum triiodothyronine/thyroxine ratio; levothyroxine dosage; adverse reactions and serious adverse reactions and events. DISCUSSION: In this pragmatic trial, participating patients follow their usual treatment at their usual hospitals. In order to collect high-quality data on the clinical course and quality of life, and to minimize missing data, an elaborate trial management system has been designed. 12 months intervention duration was selected in consideration of the primary outcome, thyroid-related quality of life. TRIAL REGISTRATION: ClinicalTrials.gov ID: NCT02013479.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rayman, M. P. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61452-9 · Cited by 3,563
Chronic Autoimmune Thyroiditis
Dayan, C. M., & Daniels, G. H. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350206 · Cited by 904 · cited 1×
“Background Chronic autoimmune thyroiditis (AIT), also known as chronic lymphocytic thyroiditis or Hashimoto’s thyroiditis, is a common autoimmune disease, which most often leads to impaired function of the thyroid gland [1].”
Saravanan, P., Chau, W. ‐., Roberts, N., Vedhara, K., Greenwood, R., & Dayan, C. M. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01654.x · Cited by 514 · cited 1×
“Large-scale community-based studies have demonstrated impaired well-being in euthyroid patients on LT4 treatment for primary hypothyroidism, indicating that restoration of euthyroidism is not the only predictor of good quality of life in patients with AIT [15,16].”
2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism
Wiersinga, W. M., Duntas, L., Fadeyev, V., Nygaard, B., & Vanderpump, M. P. J. (2012) · European Thyroid Journal · doi:10.1159/000339444 · Cited by 437
Gärtner, R., Gasnier, B. C. H., Dietrich, J. W., Krebs, B., & Angstwurm, M. W. A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.4.8421 · Cited by 389 · cited 1×
“Meanwhile, in the majority of 13 randomized clinical trials, selenium, in various formulations, effectively decreased serum TPO-Ab concentrations in AIT patients [28-40].”
Epidemiology of subtypes of hypothyroidism in Denmark.
Carlé, A., Laurberg, P., Pedersen, I. B., Knudsen, N., Perrild, H., Ovesen, L., Rasmussen, L. B., & Jorgensen, T. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02068 · Cited by 195 · cited 12×
“AIT has been estimated to account for around 85% of these patients and is 8 to 9 times more frequent in women than in men [5,6].”
InfluentialPanicker, V., Evans, J., Bjøro, T., Åsvold, B. O., Dayan, C. M., & Bjerkeset, O. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03521.x · Cited by 121 · cited 1×
“Large-scale community-based studies have demonstrated impaired well-being in euthyroid patients on LT4 treatment for primary hypothyroidism, indicating that restoration of euthyroidism is not the only predictor of good quality of life in patients with AIT [15,16].”
Krysiak, R., & Okopien, B. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2986 · Cited by 117 · cited 1×
“Meanwhile, in the majority of 13 randomized clinical trials, selenium, in various formulations, effectively decreased serum TPO-Ab concentrations in AIT patients [28-40].”
Thvilum, M., Brandt, F., Almind, D., Christensen, K., Brix, T. H., & Hegedüs, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075789 · Cited by 92 · cited 1×
“In fact, hypothyroidism, even when adequately treated, is associated with increased morbidity and mortality [17-20].”
Self-citationWatt, T., Hegedüs, L., Rasmussen, Å. K., Groenvold, M., Bonnema, S. J., Bjorner, J. B., & Feldt-Rasmussen, U. (2007) · Thyroid · doi:10.1089/thy.2007.0069 · Cited by 89 · cited 1×
“Subse-quently, we have developed such a thyroid-related quality of life questionnaire, ThyPRO, to overcome the shortcomings and lack of validation of earlier HRQL questionnaires [11-14].”
Self-citation
Cited by
Selenium and Thyroid Disease: From Pathophysiology to Treatment
Ventura, M., Melo, M., & Carrilho, F. (2017) · International Journal of Endocrinology · doi:10.1155/2017/1297658 · Cited by 337
Selenium in thyroid disorders—essential knowledge for clinicians
Winther, K. H., Rayman, M. P., Bonnema, S. J., & Hegedüs, L. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0311-6 · Cited by 288
Self-citationThe Pathogenesis of Hashimoto’s Thyroiditis: Further Developments in our Understanding
Ajjan, R. A., & Weetman, A. P. (2015) · Hormone and Metabolic Research · doi:10.1055/s-0035-1548832 · Cited by 259
Köhrle, J. (2015) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000190 · Cited by 195
Winther, K. H., Cramon, P., Watt, T., Bjorner, J. B., Ekholm, O., Feldt-Rasmussen, U., Groenvold, M., Rasmussen, Å. K., Hegedüs, L., & Bonnema, S. J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0156925 · Cited by 152
“In a recent study both depressive symptoms and sexual dysfunction were related to subclinical hypothyroidism in female patients with AIT [29].”
BackgroundInfluentialSelf-citation
Metadata
- Authors
- Winther, K. H., Watt, T., Bjørner, J. B., Cramon, P., Feldt-Rasmussen, U., Gluud, C., Gram, J., Groenvold, M., Hegedüs, L., Knudsen, N., Rasmussen, Å. K., & Bonnema, S. J.
- Venue
- Trials
- Published
- 2014-04-09
- Volume
- 15
- Issue
- 1
- Pages
- 115-115
- ISSN
- 1745-6215 (ISSN-L)
- OpenAlex
- W2125191639
- Cited by
- 83
- References
- 12
- FWCI
- 7.42
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The chronic autoimmune thyroiditis quality of life selenium trial (CATALYST): study protocol for a randomized controlled trial. https://app.cochat.ai/papers/10.1186/1745-6215-15-115
- The paper
- Winther, K. H., Watt, T., Bjørner, J. B., Cramon, P., Feldt-Rasmussen, U., Gluud, C., Gram, J., Groenvold, M., Hegedüs, L., Knudsen, N., Rasmussen, Å. K., & Bonnema, S. J. (2014). The chronic autoimmune thyroiditis quality of life selenium trial (CATALYST): study protocol for a randomized controlled trial. Trials. https://doi.org/10.1186/1745-6215-15-115
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.